Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Replaces Avandia REMS Distribution Restrictions With Prescriber Training

This article was originally published in The Pink Sheet Daily

Executive Summary

Comforted by the re-adjudicated RECORD results, agency directs rosiglitazone sponsors to provide training “based on the current state of knowledge” about the diabetes drug’s cardiovascular risk but eliminates the requirement that links drug access to provider, pharmacy and patient enrollment in the REMS.


Related Content

Can A REMS Mitigate CV Risks? Avandia, Meridia Offer Point, Counterpoint
Melior, Bukwang Seek Diabetes Edge With Novel Insulin Sensitizer
When To End A REMS? Soliris Review Stirs Debate On How To Scale Back
Industry To FDA: Rethink Diabetes Drug CV Safety Requirements
Shared REMS Systems Show Challenges Of Standardization – Could PDUFA V Help?
Avandia Review Endorsement Aided By Good Data, Cultural Shift On Safety
Avandia Committee Gives Split Vote To Drug, But FDA Clear Winner
Avandia REMS Limits Access To Mail Order Pharmacies Beginning In November
FDA, EMA Decisions On Avandia Reflect The Power Of REMS
Avandia Advisory Committee Re-Review Reflects Well On FDA


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts